#biotech

🏢Release 📈 Stocks

Innovent Biologics Gains NMPA Nod for Sintilimab in Advanced Melanoma

October 26, 2026 (15 days ago)

Innovent Biologics advances its oncology pipeline as the NMPA accepts a new indication application for sintilimab to treat advanced melanoma, signaling potential…

01801.HK

🌍 ASIA Read More →

🏢Release 📈 Stocks

Genmab and Incyte Partner to Test New Colorectal Cancer Treatment Combo

October 25, 2026 (15 days ago)

Biotech firms Genmab and Incyte are joining forces to test a new combination therapy targeting KRAS G12D-mutated colorectal cancer, a common and…

GMAB INCY

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Genmab Reports Strong Phase 2 Data for Petosemtamab in Colorectal Cancer

October 25, 2026 (16 days ago)

Genmab's petosemtamab shows durable clinical activity in metastatic colorectal cancer, with 81% response rates in specific patient subgroups, bolstering the firm's Phase…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Eli Lilly Reports Positive Phase Data for Olomorasib in NSCLC Treatment

October 25, 2026 (16 days ago)

Eli Lilly's olomorasib shows clinical promise in first-line NSCLC treatment, potentially bolstering the company's oncology pipeline following positive ESMO data.

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Innovent Biologics Presents Phase 1 Data for IBI3001 at ESMO Congress

October 25, 2026 (16 days ago)

Innovent Biologics shares Phase 1 clinical trial results for IBI3001 at the ESMO congress, marking a key milestone in the company's oncology…

01801.HK

🌍 ASIA Read More →

🏢Release 📈 Stocks

Eli Lilly Reports 79% Response Rate for Ovarian Cancer Drug Candidate

October 24, 2026 (17 days ago)

Eli Lilly's sofetabart mipitecan shows strong clinical efficacy in ovarian cancer trials, achieving a 100% disease control rate in combination therapy.

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Warhound Launches With $200 Million to Develop Genetically Enhanced K9s

October 23, 2026 (17 days ago)

Warhound enters the defense sector with $200 million to produce cybernetically enhanced military dogs, targeting improved operational performance and domestic supply chain…

Warhound

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Hansa Biopharma Reports 90% Graft Survival Rate in Idefirix Study

October 23, 2026 (17 days ago)

Hansa Biopharma's Idefirix achieves 90% graft failure-free survival at 12 months, with patient survival rates hitting 98%, signaling strong clinical validation for…

HNSA

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Genmab Reports 71% Risk Reduction in Phase 3 Ovarian Cancer Trial

October 23, 2026 (18 days ago)

Genmab's Rina-S hit primary endpoints in a Phase 3 ovarian cancer trial, showing a 71% reduction in disease progression risk and paving…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Jazz Pharmaceuticals Reports 40% Three-Year Survival Rate for Ziihera Combo

October 23, 2026 (18 days ago)

Jazz Pharmaceuticals and partner BeiGene report a 27-month median overall survival for Ziihera-based regimens in HER2+ gastroesophageal cancer, bolstering the case for…

JAZZ BGNE

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals Presents Phase 1 Data for ATNM-400 at ESMO 2026

October 23, 2026 (18 days ago)

Actinium Pharmaceuticals showcases its HER3-targeted alpha radiotherapy, ATNM-400, in a Phase 1 study targeting metastatic castration-resistant prostate cancer at the ESMO 2026…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Alebund Pharmaceuticals Unveils Phase IIb Trial Design for AP306 Candidate

October 23, 2026 (18 days ago)

Alebund Pharmaceuticals and partner R1 Therapeutics have detailed the Phase IIb trial design for AP306, marking a key procedural milestone in the…

09637.HK

🌍 ASIA Read More →